Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emtricitabine vs Abacavir in HIV-1
NCT00002362Phase 3Suspended
- Sponsor
- Triangle Pharmaceuticals, Inc.
- Start
- Aug 1999
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of emtricitabine in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Triangle Pharmaceuticals, Inc. Primary endpoints: Viral Load at 48 weeks and CD4+ Cell Count at 48 weeks. Started Aug 1999; status: suspended.
02
Drugs
emtricitabine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00002362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002362.